Peer-reviewed veterinary case report
Signs and treatment outcomes for cats with myeloma-related disorder
By Cannon, Claire M et al.·Published in Journal of the American Animal Hospital Association·2015·From the Department of Veterinary Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical Signs, Treatment, and Outcome in Cats with Myeloma-Related Disorder Receiving Systemic Therapy.
- Species:
- cat
Plain-English summary
A group of cats diagnosed with a rare blood disorder called myeloma-related disorder (MRD) received treatment to see how well they responded. Thirteen of the fifteen cats were given either melphalan or cyclophosphamide, sometimes with corticosteroids. The results showed that about 71% of the cats treated with melphalan and 83% treated with cyclophosphamide responded positively to the treatment. While melphalan often had to be stopped due to side effects, the combination of cyclophosphamide and corticosteroids was generally well tolerated and could be a good first choice for treatment.
People also search for: cat myeloma treatment · cat blood disorder symptoms · cyclophosphamide for cats
Abstract
Myeloma-related disorder (MRD) is an uncommon disease in cats, for which there is no established standard of care. In this retrospective study, we evaluated presentation, response to treatment, and toxicity in cats with MRD receiving systemic treatment. Previously reported prognostic factors were evaluated for their impact on survival in cats receiving chemotherapy. Of fifteen cases identified, thirteen received melphalan or cyclophosphamide +/- corticosteroids as first-line therapy. Chlorambucil was commonly used as rescue therapy in cats with progressive disease, or in cases of chemotherapy-related toxicity with first line agents. Overall response rates were 71% and 83% for melphalan- and cyclophosphamide-treated cats, respectively. Discontinuation of melphalan due to toxicity was common. Survival times for cats initially treated with melphalan or cyclophosphamide were not significantly different (median 252 and 394 days, respectively), and no statistically significant prognostic factors were identified. This study suggests that the combination of cyclophosphamide and corticosteroids is well tolerated and may be considered as first-line therapy for cats with systemic MRD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26083436/